[go: up one dir, main page]

MA31634B1 - Anticorps humains en cd20 humain et leur procede d'utilisation - Google Patents

Anticorps humains en cd20 humain et leur procede d'utilisation

Info

Publication number
MA31634B1
MA31634B1 MA32651A MA32651A MA31634B1 MA 31634 B1 MA31634 B1 MA 31634B1 MA 32651 A MA32651 A MA 32651A MA 32651 A MA32651 A MA 32651A MA 31634 B1 MA31634 B1 MA 31634B1
Authority
MA
Morocco
Prior art keywords
human
antibody
antigen
disease
binding fragment
Prior art date
Application number
MA32651A
Other languages
Arabic (ar)
English (en)
Inventor
Joel H Martin
Li-Hsien Wang
Sean Stevens
Erin M Allison
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA31634B1 publication Critical patent/MA31634B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention concerne un anticorps humain ou un fragment de liaison à un antigène d'un anticorps qui se lie spécifiquement au cd20 humain et est apte à induire une cytotoxicité dépendante de complément (cdc) et à multiplier le temps de survie sans symptôme par 2 à environ 9 ou plus que chez des animaux témoins traités dans un modèle de souris de lymphome humain. L'anticorps ou son fragment de liaison à un antigène est utile dans le procédé thérapeutique d'une maladie ou affection véhiculée par cd20 telle que, par exemple, le lymphome non hodgkinien, la polyarthrite rhumatoïde, le lupus érythémateux systémique, la maladie de crohn, la leucémie lymphocytaire chronique et les maladies inflammatoires.
MA32651A 2007-07-31 2010-02-24 Anticorps humains en cd20 humain et leur procede d'utilisation MA31634B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96281107P 2007-07-31 2007-07-31
US6799408P 2008-03-03 2008-03-03
PCT/US2008/071709 WO2009018411A1 (fr) 2007-07-31 2008-07-31 Anticorps humains en cd20 humain et leur procédé d'utilisation

Publications (1)

Publication Number Publication Date
MA31634B1 true MA31634B1 (fr) 2010-08-02

Family

ID=40010730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32651A MA31634B1 (fr) 2007-07-31 2010-02-24 Anticorps humains en cd20 humain et leur procede d'utilisation

Country Status (28)

Country Link
US (3) US7879984B2 (fr)
EP (1) EP2178916B1 (fr)
JP (1) JP5588865B2 (fr)
KR (1) KR101561020B1 (fr)
CN (1) CN101809037B (fr)
AU (1) AU2008282152B2 (fr)
BR (1) BRPI0813985B1 (fr)
CA (1) CA2695199C (fr)
CO (1) CO6260105A2 (fr)
CR (1) CR11243A (fr)
DK (1) DK2178916T3 (fr)
DO (1) DOP2010000037A (fr)
EC (1) ECSP10010005A (fr)
ES (1) ES2527297T3 (fr)
GT (1) GT201000026A (fr)
HN (1) HN2010000202A (fr)
MA (1) MA31634B1 (fr)
ME (1) ME00973B (fr)
MX (1) MX2010000970A (fr)
MY (1) MY147651A (fr)
NI (1) NI201000016A (fr)
NZ (1) NZ583019A (fr)
PL (1) PL2178916T3 (fr)
RU (1) RU2486205C2 (fr)
SV (1) SV2010003468A (fr)
TN (2) TN2010000054A1 (fr)
WO (1) WO2009018411A1 (fr)
ZA (1) ZA201000545B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
WO2010132532A1 (fr) * 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps réagissant à la surface des lymphocytes b
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2798950B2 (fr) 2009-07-08 2023-03-22 Kymab Limited Modèles animaux et molécules thérapeutiques
KR101862277B1 (ko) 2009-12-21 2018-06-01 리제너론 파마슈티칼스 인코포레이티드 인간화된 ＦｃγＲ 마우스
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
EP2761008A1 (fr) 2011-09-26 2014-08-06 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN111533804A (zh) * 2012-02-06 2020-08-14 印希彼有限公司 Cd47抗体及其使用方法
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI745610B (zh) * 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140140991A1 (en) * 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
JP2016509012A (ja) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｅｒｋ阻害剤およびそれらの使用
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
CA2909579A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Therapie combinee comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide pour le traitement d'un cancer
KR102223060B1 (ko) 2013-04-17 2021-03-05 시그날 파마소티칼 엘엘씨 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9119854B2 (en) 2013-05-03 2015-09-01 Celgene Corporation Methods for treating cancer using combination therapy
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EP3051942B1 (fr) 2013-10-01 2020-09-02 Kymab Limited Modèles d'animaux et molécules thérapeutiques
CN113995843A (zh) * 2013-11-07 2022-02-01 豪夫迈·罗氏有限公司 抗cd20抗体与btk抑制剂的组合疗法
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
HUE071048T2 (hu) 2014-11-17 2025-07-28 Regeneron Pharma Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20250007038A (ko) 2015-10-02 2025-01-13 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017112775A1 (fr) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
WO2018016881A1 (fr) * 2016-07-19 2018-01-25 (주)아이벤트러스 Protéines bispécifiques et leurs procédés de préparation
EP3504328A1 (fr) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Modification de protéines de cellules hôtes
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018118754A1 (fr) * 2016-12-19 2018-06-28 Vanderbilt University Anticorps dirigés contre la conformation de pré-fusion de protéine du virus respiratoire syncytial humain et leurs métodes d'utilisation
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CA3054632A1 (fr) 2017-03-30 2018-10-04 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libere a l'aide d'un dispositif ingerable
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
WO2019036855A1 (fr) 2017-08-21 2019-02-28 Adagene Inc. Molécules anti-cd137 et leur utilisation
JP7321159B2 (ja) 2017-12-22 2023-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 薬剤生成物不純物を特性決定するためのシステム及び方法
AU2019215363A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
SG11202006310PA (en) 2018-02-28 2020-07-29 Regeneron Pharma Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
PL3768709T3 (pl) 2018-03-19 2024-05-20 Regeneron Pharmaceuticals, Inc. Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
BR112020024296A2 (pt) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
TWI866924B (zh) 2018-08-30 2024-12-21 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
PL3844189T3 (pl) 2018-08-31 2025-03-31 Regeneron Pharmaceuticals, Inc. Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
EP3852788A1 (fr) 2018-09-17 2021-07-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Récepteurs antigéniques chimériques bicistroniques ciblant cd19 et cd20 et leurs utilisations
CA3115139A1 (fr) 2018-10-01 2020-04-09 Adicet Bio Inc. Compositions et procedes concernant des cellules t .gamma..delta. genetiquement modifiees ou non modifiees pour le traitement de tumeurs hematologiques
WO2020106754A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
SG11202104103XA (en) 2019-01-16 2021-05-28 Regeneron Pharma Methods for characterizing disulfide bonds
CN113785203A (zh) 2019-05-13 2021-12-10 里珍纳龙药品有限公司 改进的竞争性配体结合测定
IL291020B2 (en) 2019-09-24 2025-04-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP4065086B1 (fr) 2019-11-25 2026-01-28 Regeneron Pharmaceuticals, Inc. Formulations à libération prolongée utilisant des émulsions non aqueuses
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
JP7342279B2 (ja) 2020-01-21 2023-09-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グリコシル化タンパク質の電気泳動のための脱グリコシル化方法
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US12163122B2 (en) 2020-08-31 2024-12-10 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
IL303027A (en) 2020-11-25 2023-07-01 Regeneron Pharma Sustained release formulations by creating a non-aqueous membrane emulsion
EP4262757A1 (fr) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication de microgels encapsulant des protéines
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
EP4302098A1 (fr) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de quantification et de modification de la viscosité de protéines
CN117529505A (zh) 2021-03-24 2024-02-06 美国卫生和人力服务部 设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途
IL305731A (en) 2021-03-26 2023-11-01 Regeneron Pharma Methods and systems for developing mixing protocols
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
MX2024004107A (es) 2021-10-07 2024-04-19 Regeneron Pharma Sistemas y metodos para modelar y controlar el ph.
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
CN118176167A (zh) 2021-10-26 2024-06-11 瑞泽恩制药公司 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法
EP4493921A1 (fr) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Procédés et systèmes permettant d'analyser des variants polypeptidiques
WO2023196903A1 (fr) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Molécules bispécifiques de liaison à l'antigène qui se lient et cd3 et antigènes associés à une tumeur (taa) et leurs utilisations
WO2023215560A1 (fr) 2022-05-05 2023-11-09 Atoosa Corporation Dispositif de mise en prise de récepteur multivalent de cellule tumorale/cellule immunitaire-bio-nanoparticule (timre-bnp)
KR20250124178A (ko) 2022-12-16 2025-08-19 리제너론 파아마슈티컬스, 인크. 크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024158880A1 (fr) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Procédés de modélisation de stabilité de composition de protéine liquide
WO2024163708A1 (fr) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Fractionnement en continu à flux asymétrique avec spectrométrie de masse pour analyse biomacromoléculaire
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
IL322815A (en) 2023-02-28 2025-10-01 Juno Therapeutics Inc Cell therapy for the treatment of systemic autoimmune diseases
EP4626447A1 (fr) 2023-03-31 2025-10-08 AbelZeta Inc. Récepteurs antigéniques chimériques bispécifiques ciblant cd20 et bcma
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (fr) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilisation à l'aide d'une nucléation contrôlée
WO2025085594A1 (fr) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Purification rapide d'anticorps monoclonal à partir d'un matériau de culture cellulaire en amont dans un procédé
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025160340A2 (fr) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Immunosuppression combinée pour inhiber une réponse immunitaire et pour permettre une administration et une réadministration d'immunogène
WO2025160324A2 (fr) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour utiliser des agents de déplétion des cellules plasmatiques et/ou des agents de déplétion des lymphocytes b pour supprimer une réponse d'anticorps anti-aav hôte et permettre la transduction et le redosage d'aav
WO2025166281A1 (fr) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Plateforme d'analyse par spectrométrie de masse à détection de charge d'aavs
WO2025175164A1 (fr) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Procédés de production de substances médicamenteuses formulées concentrées comprenant des protéines, et substance médicamenteuse formulée concentrée fabriquée par les procédés
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
WO2025194043A1 (fr) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate et polyoxyéthylène sorbitane utilisés en tant qu'excipients pour formulations de protéines stables
WO2025259840A1 (fr) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Procédés et systèmes de chromatographie mise à l'échelle

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000009160A1 (fr) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Therapies d'association contre les lymphomes malins a cellules b par l'administration d'anticorps anti-cd20
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1519959B1 (fr) 2002-02-14 2014-04-02 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
US20030233797A1 (en) * 2002-06-25 2003-12-25 Anderson Dean A. Air handling system including shroud and grille, and method of use
CA2502552C (fr) * 2002-10-17 2019-02-12 Genmab A/S Anticorps monoclonaux humains anti-cd20
US6736137B1 (en) * 2003-02-28 2004-05-18 Tmr-A, Llc Protective hooded respirator with oral-nasal cup breathing interface
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP2960251A1 (fr) 2003-05-09 2015-12-30 Duke University Anticorps spécifiques de CD20 et leurs méthodes d'utilisation
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
DE10334793A1 (de) * 2003-07-30 2005-02-24 BSH Bosch und Siemens Hausgeräte GmbH Geschirrspülmaschine
ZA200601218B (en) 2003-08-29 2007-05-30 Genentech Inc Anti-CD20 therapy of ocular disorders
CA2549237A1 (fr) 2003-12-19 2005-07-07 Genentech, Inc. Detection de cd20 lors d'un rejet de transplant
WO2005103081A2 (fr) * 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
RU2006142857A (ru) 2004-05-05 2008-06-10 Дженентек, Инк. (Us) Профилактика аутоиммунного заболевания
AR049292A1 (es) 2004-06-04 2006-07-12 Genentech Inc Metodo para tratar lupus con un anticuerpo cd20
WO2006041680A2 (fr) 2004-10-05 2006-04-20 Genentech, Inc. Methode de traitement de l'angeite
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CN1331888C (zh) * 2005-03-02 2007-08-15 中国人民解放军军事医学科学院生物工程研究所 一种抗人b细胞淋巴瘤的单链双特异性抗体
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
MX2007012989A (es) 2005-04-22 2008-01-11 Genentech Inc Metodo para tratar la demencia o la enfermedad de alheimer.
US20070014720A1 (en) 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof

Also Published As

Publication number Publication date
CA2695199C (fr) 2016-07-19
US8329181B2 (en) 2012-12-11
TN2010000054A1 (en) 2011-09-26
PL2178916T3 (pl) 2015-08-31
ECSP10010005A (es) 2010-03-31
AU2008282152B2 (en) 2013-12-19
MY147651A (en) 2012-12-31
ME00973B (fr) 2012-06-20
JP2010535033A (ja) 2010-11-18
US20120100145A1 (en) 2012-04-26
WO2009018411A1 (fr) 2009-02-05
TN2010000056A1 (en) 2011-09-26
RU2486205C2 (ru) 2013-06-27
US20110081681A1 (en) 2011-04-07
MX2010000970A (es) 2010-03-09
GT201000026A (es) 2012-04-23
DOP2010000037A (es) 2017-07-31
EP2178916B1 (fr) 2014-12-17
KR20100057012A (ko) 2010-05-28
BRPI0813985B1 (pt) 2022-05-10
BRPI0813985A2 (pt) 2017-08-01
CO6260105A2 (es) 2011-03-22
EP2178916A1 (fr) 2010-04-28
HK1141811A1 (en) 2010-11-19
CN101809037A (zh) 2010-08-18
DK2178916T3 (en) 2015-01-12
US20090035322A1 (en) 2009-02-05
AU2008282152A1 (en) 2009-02-05
CA2695199A1 (fr) 2009-02-05
SV2010003468A (es) 2010-08-10
ZA201000545B (en) 2011-04-28
US8097713B2 (en) 2012-01-17
ES2527297T3 (es) 2015-01-22
NZ583019A (en) 2011-05-27
HN2010000202A (es) 2012-08-15
RU2010107175A (ru) 2011-09-10
US7879984B2 (en) 2011-02-01
CN101809037B (zh) 2014-01-15
KR101561020B1 (ko) 2015-10-26
JP5588865B2 (ja) 2014-09-10
NI201000016A (es) 2010-07-27
CR11243A (es) 2010-05-19

Similar Documents

Publication Publication Date Title
MA31634B1 (fr) Anticorps humains en cd20 humain et leur procede d'utilisation
Brühl et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells
Lewis Jr et al. Genetic and cellular evidence of decreased inflammation associated with reduced incidence of posttraumatic arthritis in MRL/MpJ mice
EP2754671A3 (fr) Anticorps anti MIF
Stolina et al. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
MA30047B1 (fr) Procede destine a traiter une lesion articulaire
IL178121A (en) Anti-cs-1 antibodies for the treatment of multiple myeloma
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
Oberoi et al. Anti-tumor necrosis factor-α therapy increases plaque burden in a mouse model of experimental atherosclerosis
MXPA05012011A (es) Uso terapeutico de anticuerpos anti-cs1.
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
CY1112858T1 (el) Θεραπευτικο ανθρωπινο αντι-ιl-1r1 μονοκλωνικο αντισωμα
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE60328195D1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
Wondimu et al. Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis
JP2010500380A5 (fr)
Jung et al. DJ-1 protein regulates CD3+ T cell migration via overexpression of CXCR4 receptor
Byng-Maddick et al. Tumor necrosis factor (TNF) bioactivity at the site of an acute cell-mediated immune response is preserved in rheumatoid arthritis patients responding to anti-TNF therapy
Wang et al. Low‐Dose Staphylococcal Enterotoxin C2 Mutant Maintains Bone Homeostasis via Regulating Crosstalk between Bone Formation and Host T‐Cell Effector Immunity
Migita et al. Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes